Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ribavirin

FDA-approved product (for solution, inhalation), marketed as Copegus, Rebetol, Ribasphere and 2 more.

Registered studies
50+
Lab records
2
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Ribavirin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Cirrhosis of liver
  • Fibrosis
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
FDA pharmacologic class
Nucleoside Analog Antiviral FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP01; FDA class Nucleoside Analog Antiviral

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Ribavirin, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA19.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli5.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae5.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis22.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 0 of 1 lab record
  • K. pneumoniae: measured active in 0 of 1 lab record
Open Ribavirin in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ribavirin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)

    NCT01344889 · start 2009-10

    Registered record
    Registry ID
    NCT01344889
    Conditions
    Hepatitis C, Chronic
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-10
    Completion
    2013-06
    Enrolment
    4,459

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

    NCT00938860 · start 2009-09

    Registered record
    Registry ID
    NCT00938860
    Conditions
    Hepatitis C; Liver Transplantation
    Interventions
    cyclosporin (Neoral); tacrolimus (Prograf)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    2013-05
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Liver Transplantation
    Interventioncyclosporin (Neoral); tacrolimus (Prograf)
    PhasePhase 4
    Registry statusCompleted

  • An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

    NCT02557646 · start 2009-05

    Registered record
    Registry ID
    NCT02557646
    Conditions
    Hepatitis C, Chronic
    Interventions
    Peginterferon alfa-2a; Ribavirin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-05
    Completion
    2014-03
    Enrolment
    697

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionPeginterferon alfa-2a; Ribavirin
    PhaseNot recorded
    Registry statusCompleted

  • Ribavirin for Hemorrhagic Fever With Renal Syndrome

    NCT00623168 · start 2008-02

    Registered record
    Registry ID
    NCT00623168
    Conditions
    Hemorrhagic Fever With Renal Syndrome
    Interventions
    Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2008-02
    Completion
    2019-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemorrhagic Fever With Renal Syndrome
    InterventionRibavirin
    PhasePhase 2
    Registry statusWithdrawn

  • An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

    NCT00528528 · start 2007-10

    Registered record
    Registry ID
    NCT00528528
    Conditions
    Chronic Hepatitis C
    Interventions
    Telaprevir; Peg-IFN-alfa-2a; Peg-IFN-alfa-2b; Ribavirin (RBV) tablet; Ribavirin (RBV) capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-10
    Completion
    2009-08
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionTelaprevir; Peg-IFN-alfa-2a; Peg-IFN-alfa-2b; Ribavirin (RBV) tablet +1 more
    PhasePhase 2
    Registry statusCompleted

  • Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders

    NCT00624325 · start 2007-07

    Registered record
    Registry ID
    NCT00624325
    Conditions
    Chronic Hepatitis C
    Interventions
    interferon alfa-2b; interferon alfa-2b; interferon alfa-2b
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-07
    Completion
    2010-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    Interventioninterferon alfa-2b; interferon alfa-2b; interferon alfa-2b
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)

    NCT00493805 · start 2007-04

    Registered record
    Registry ID
    NCT00493805
    Conditions
    Hepatitis C, Chronic; Insulin Resistance
    Interventions
    Combination of pegylated interferon alfa-2b and ribavirin; Combination of pegylated interferon alfa-2b and ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2007-04
    Completion
    2009-10
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic; Insulin Resistance
    InterventionCombination of pegylated interferon alfa-2b and ribavirin; Combination of pegylated interferon alfa-2b and ribavirin
    PhasePhase 4
    Registry statusTerminated

  • A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

    NCT00420784 · start 2007-02

    Registered record
    Registry ID
    NCT00420784
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Ribavirin; Pegylated Interferon Alfa 2a; Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    2009-04
    Enrolment
    465

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Ribavirin; Pegylated Interferon Alfa 2a; Matching Placebo
    PhasePhase 2
    Registry statusCompleted

  • Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy

    NCT00437684 · start 2007-02

    Registered record
    Registry ID
    NCT00437684
    Conditions
    HIV Infections; Hepatitis C
    Interventions
    LPV/r; PEG-IFNa 2a; Ribavirin; NUCS
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2007-02
    Completion
    2010-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Hepatitis C
    InterventionLPV/r; PEG-IFNa 2a; Ribavirin; NUCS
    PhasePhase 3
    Registry statusUnknown

  • Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.

    NCT00323804 · start 2006-05

    Registered record
    Registry ID
    NCT00323804
    Conditions
    Hepatitis C, Chronic; Liver Fibrosis
    Interventions
    Peginterferon alfa-2b; Ribavirin; Ribavirin-Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2006-05
    Completion
    2013-03
    Enrolment
    372

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic; Liver Fibrosis
    InterventionPeginterferon alfa-2b; Ribavirin; Ribavirin-Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4

    NCT00502099 · start 2006-01

    Registered record
    Registry ID
    NCT00502099
    Conditions
    Hepatitis C
    Interventions
    Pegylated interferon alpha 2a; Ribavirin; Pegylated interferon alpha 2 b plus ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-01
    Completion
    2009-05
    Enrolment
    217

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionPegylated interferon alpha 2a; Ribavirin; Pegylated interferon alpha 2 b plus ribavirin
    PhasePhase 4
    Registry statusCompleted

  • Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin

    NCT00230854 · start 2005-08

    Registered record
    Registry ID
    NCT00230854
    Conditions
    Chronic Hepatitis C; Hepatitis, Viral, Human
    Interventions
    EMZ702
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-08
    Completion
    2007-07
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C; Hepatitis, Viral, Human
    InterventionEMZ702
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)

    NCT00724295 · start 2005-04

    Registered record
    Registry ID
    NCT00724295
    Conditions
    Hepatitis C, Chronic; Hepatitis C
    Interventions
    peginterferon alfa-2b; ribavirin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-04
    Completion
    2008-12
    Enrolment
    1,077

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic; Hepatitis C
    Interventionpeginterferon alfa-2b; ribavirin
    PhaseNot recorded
    Registry statusCompleted

  • Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)

    NCT00705107 · start 2004-11

    Registered record
    Registry ID
    NCT00705107
    Conditions
    Hepatitis C, Chronic; Hepatitis C
    Interventions
    PegIntron pen (peginterferon alfa-2b; SCH 54031); Rebetol (ribavirin; SCH 18908)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2004-11
    Completion
    2007-11
    Enrolment
    267

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic; Hepatitis C
    InterventionPegIntron pen (peginterferon alfa-2b; SCH 54031); Rebetol (ribavirin; SCH 18908)
    PhaseNot recorded
    Registry statusTerminated

  • Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

    NCT00078403 · start 2004-07

    Registered record
    Registry ID
    NCT00078403
    Conditions
    HIV Infections; Hepatitis C; Liver Disease
    Interventions
    Peginterferon alfa-2a; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-07
    Completion
    2009-02
    Enrolment
    333

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Hepatitis C; Liver Disease
    InterventionPeginterferon alfa-2a; Ribavirin
    PhasePhase 2
    Registry statusCompleted